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Introduction
Some 40 years ago while spending the night in front of TV and waiting for Neil Armstrong to step
down the lander of Apollo 11 to the surface of the moon, indeed, I could not imagine to witness,
another event of corresponding relevance for mankind in my lifetime. However, the recent report
by Siemers and colleges on slowing down progress of Alzheimer Disease of people showing mild
but proven Alzheimer symptoms by Solanezumab antibodies is of that size (Siemers et al., 2015).
Thesis: Alzheimer Disease Rests on Cell Death Induction by
Amyloid Aß Mono- and Oligomers
From my point of view the observations presented by Siemers et al. (2015) not only represent a
therapeutic breakthrough. The effects observed also broaden the understanding of the pathogenesis
of Alzheimer Disease, this by plainly pointing to induced neuronal cell death as basic in AD. The
data thus support a proposal of mine first made in 2010 (Thinnes, 2010, 2011, 2012a,b). For a highly
shematic trial to graphically demonstrate the concept see Figure 1.
Accordingly, plasmalemmal VDAC-1 (Swiss Prot. P21796) in situ works as a receptor of amyloid
Aß mono- or oligomers. In line, it has been shown that docking of those Aß forms to cell surfaces
result in an opening of cell membrane-standing VDAC-1, a process finally ending in neuronal cell
death. In consequence, whenever critical brain regions and their redundant structures are affected
this way neuronal loss must be expected. In contrary, to neutralize amyloid Aßmono- or oligomers
by adequate monoclonal antibodies should minimize Aß toxicity, in other words slow down AD
progress (Siemers et al., 2015).
The voltage dependent anion channel (VDAC) is an archaic channel and thus suggested to be
involved in housekeeping functions. The channel is well established in the outer mitochondrial
membrane, here playing its role in the intrinsic apoptotic pathway (Huang et al., 2015). It is this
way of proven relevance for Alzheimer’s Dementia (Demetrius et al., 2015).
A first report on an extra-mitochondrial expression of VDAC-1 came up in 1989 showing that
human lymphocytes carry a heavy load of the molecule in their plasmalemma. Those data were
meanwhile corroborated by studies of several laboratories using different approaches with several
cell lines and tissues: e.g., immuno-topochemistry on the light and electron microscopy level, raster
electron microscopy, mitochondrial compartment marker controlled cell membrane enrichment,
recombinant VDAC1 expression combined with GFP-labeling, voltage-clamp, and patch-clamp
studies on Xenopus oocytes and mammalian astrocytes, video monitoring of the swelling behavior
of HeLa cells; for details see Thinnes and Reymann (1997), Thinnes (2015a,b) and www.futhin.de.
A series of recent papers, from my point of view, raises cell membrane-integration of VDAC-1
beyond reasonable doubt, this by connecting plasmalemmal VDAC-1 to cell biologic mechanisms
that make the issue lucid (Fernandez-Echevarria et al., 2014; Li et al., 2014; Tewari et al., 2014).
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Concerning functions of plasmalemmal VDAC-1, after studies
focussed on the regulatory volume decrease (RVD) of HeLa
cell (Thinnes et al., 2000) or murine respiratory epithelial
cells (Okada et al., 2004), respectively, had shown that cell
membrane-integrated type-1VDAC is part of the cell volume
regulatory system of mammalian cells data came up indicating
that plasmalemmal VDAC-1 plays its role in apoptosis, too.
In a first effort Elinder et al. (2005) elaborated that
opening of VDAC-1 in the plasma membrane precedes the
activation of caspases in neuronal apoptosis, here induced
by staurosporine. In other words, the authors documented
that keeping plasmalemmal type-1VDAC of neurons closed
by different specific antibodies abolishes the apoptotic volume
decrease (AVD) of these cells.
Next, endeavors for Raquel Marin’s laboratory, Tenerife,
corroborated and widened Elinder’s data. A first study on
the toxic effect of amyloid Aß peptides on septal (SN56)
and hippocampal (HT22) neurons, on the one hand, proved
another time that blocking VDAC in cell membranes by two
different anti-porin antibodies means preventing an apoptotic
development of the cells. On the other hand, it showed that
VDAC and the estrogen receptor α (mERα) in association with
caveolin-1 co-localize and interact in cell membrane caveolae,
mERα working toward neuroprotection (Marin et al., 2007). The
topographic relationship of the molecules was further specified
demonstrating that both are integrated in caveolar lipid rafts
(Marin et al., 2008). It has, furthermore, been demonstrated
that APP and BACE1 increase interactions in neuronal lipid
rafts with progressing AD what may be explained by changes in
the physicochemical properties of these microdomains. Indeed,
that also induces a further association of, both, amyloid beta
aggregates and APP in lipid rafts (Fabelo et al., 2014; Díaz
et al., 2015). The group meanwhile presented additional data to
demonstrate that the interaction of VDAC and mERα in caveolae
from human cortex is altered in Alzheimer disease (Ramírez
et al., 2009; Marin, 2011), results which appear to be in line
with an early 2D-electrophoresis report on differences in VDAC
content of biopsies taken from normal or Alzheimer brains,
respectively (Yoo et al., 2001).
Finally, Reddy’s laboratory elaborated relevant data on
effects of amyloid Aß on VDAC-1, here mostly focussed on
mitochondrial processes (Manczak et al., 2011; Manczak and
Reddy, 2012; Reddy, 2013).
Asking for a putative mechanism of interactions of cell
membrane-standing type-1VDAC and amyloid mono- and
oligomers, it helps to notice that plasmalemmal VDAC-1 carries
a critical GxxxG motif cell outside (Thinnes, 2015a), while
amyloid Aß40/42 includes several of them in series (Thinnes,
2010, 2011). However, GxxxG motifs are established aggregation
and membrane perturbation motifs, furthermore showing
some affinity to cholesterol, phenomena broadly discussed in
Alzheimer literature (Munter et al., 2010; Gromek et al., 2014).
Concerning other VDAC/peptide interactions see Prezma et al.
(2013), Shimizu et al. (1999), www.futhin.de.
Given this background recent data on an enhancement of
BACE1 expression of hypometabolic neurons (Zhang et al.,
2010) made me ask if amyloid Aß, cut from ubiquitous
amyloid precursor protein (APP) by ß-secretase BACE1 and γ-
secretase, may spot wise induce neuronal cell death via opening
ubiquitous VDAC-1 in cell membranes of critical brain regions -
a process ending in AlzheimerDisease (Thinnes, 2010, 2011). The
authors, remembering cerebral hypometabolism and amyloid
accumulation as prevailing neuropathological characteristics of
Alzheimer Disease had tried to define effects of neuronal
hypoactivity on amyloid plaque pathogenesis in the Tg2576
transgenic mouse model of Alzheimer’s disease. They found
that unilateral naris-occlusion resulted in an elevation of the ß-
secretase BACE1 in neuronal terminals of deprived bulb and
piriform cortex in young adult mice (Zhang et al., 2010; Xiao
et al., 2015).
Conclusion
Taking for granted that (1) neuronal cells having lost their
balance show enhanced BACE1 expression and thus increased Aß
production, (2) amyloid Aß mono- and/or oligomers dock to cell
membrane-standing type-1VDAC of neuronal cells via GxxxG
motifs, (3) docking reactions result in plasmalemmal VDAC-1
channel opening followed by a form of extrinsic cell death, and
(4) Solanezumab antibodies neutralize Aß oligomers by agonist
scavenging, a revised version of the amyloid cascade hypothesis
of Alzheimer pathogenesis comes up.
Accordingly, familial as well as sporadic Alzheimer’s disease—
downstream of APP processing—can be seen as resting on a form
of extrinsic induced cell death, this via opening cell membrane-
standing VDAC-1 (= receptor). The process is boosted by
excessive amyloid Aß (= agonist) production via increased
FIGURE 1 | Model on the putative interaction of plasmalemmal VDAC-1
and Aß monomers via GxxxG motifs. Highly schematic two-dimensional
projections of human type-1VDAC summarizing data from my own lab and the
laboratories of Vito De Pinto, Roland Benz, Varda Shoshan-Barmatz, Carmen
Mannella, and Jeff Abramson; modified fom Thinnes (2015b). Fully closed
state and open state of native VDAC-1 are compared. Noteworthy, the GxxxG
motif has been shown to work as an ATP binding site may putatively figure as
a peptide interaction/membrane perturbation motif, too.
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processing of the amyloid precursor protein (APP) of weakening
cells of critical brain regions.
However, the synopsis of a series of solid data from
several laboratories helps to understand the phenomenology and
pathogenesis of either form of AD. Phenotypically mild at the
beginning, increasing brain function disturbances evidenced by
worsening stages of the disease over time point to a progressive
process on the somatic level.
First singular or just a few cells being affected, over time a
burden of cell deaths accumulates that finally ends in Alzheimer’s
Dementia whenever critical brain regions and their redundant
structures are affected (Jean et al., 2015). In line, to block free
amyloid by specific antibodies allows slowing down Alzheimer’s
Dementia as recently indicated by the nowadays moon lading of
Siemers and colleges.
Finally, the model presented at least formally allows explain
the reverse relationship of AD and cancer by pointing to
processes (Thinnes, 2012a,b; Chiu et al., 2015; Ganguli, 2015)
which may work in parallel to mitochondria related events in
Alzheimer pathogenesis as proposed by Demetrius et al. (2015).
However, my hope is that looking on Alzheimer pathogenesis
in the context of induced cell death will stimulate the field, this
the more as recent literature indicates that amyloid Aß may work
this way in other places (Martí-Fàbregas et al., 2014; Kaffashian
et al., 2015; Zetterberg, 2015).
While this manuscript was under review a publication
appeared that, from my point of view, adds further relevant
observations on effects of antibodies on amyloid building. The
study presented by Liu et al. (2015) reports on three monoclonal
antibody preparations elaborated against different epitopes inside
the amyloid Aß peptide. One of those called 6E10 a) in vitro
disaggregates artificial amyloid fibrils and thus increases the
number of Aß oligomers, while b) the injection of co-incubates
into the lateral ventricle of 6-month-old C57 mice increased the
neurotoxicity in vivo.
However, to raise amyloid Aß oligomers increases the risk of
their docking to plasmalemmal VDAC-1 finally resulting in the
induction of accumulating neuronal cell deaths. From here: To
raise amyloid Aß oligomers accelerates AD progress. The authors
call the phenomenon dust-raising.
From here, it is tempting to think Alzheimer plaques
formation as a salutary form of wipe-the-dust procedure thatmay
even protect from Alzheimer Dementia. In other words: does
plaque formation work as a buckler?
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